The stimulatory effect of recombinant human insulin-like growth factor-I (rhIGF-I) and recombinant human insulin-like growth-factor-binding protein-1 (rhIGFBP-1) on wound healing was assessed using diabetic db/db mice and normal rabbits. Full-thickness wounds of 6 mm diameter were prepared on the backs of diabetic C57BL/KsJ db /db mice and on the inner sides of normal rabbit ears. Various concentrations of rhIGF-I and/or rhIGFBP-1 were applied locally to the open wounds of db/db mice once daily for 5 d and t o the covered wounds of normal rabbits once after wounding. Sections of the wounds were evaluated histologically on the seventh or eighth day by measuring re-epithelialization (%), area of granulation tissue (mm2), and capillary numbers. Wound r e pair was accelerated by each of the t reatment s in d escending order of rhIGF-I plus rhIGFBP-1, r h I GF -I, rhIGFBP-1 , and vehicle alone. In db/db mice, t he combination of 50 ILg rhIGF-I and 165 ILg r h I GFBP-1 ound healing proceeds with inflammation and granulation tissue formation, followed by extracellular matrix deposition and remodeling [1] . The process involves the interactions of keratinocytes, fibroblasts , and inflammatory cells that have migrated to the wound site. Biologically active su bstances secreted from these cells modify the woundhealing p rocess [1] . Recent studies suggested that several growth factors released from these cells are involved in the healing process and that application of exogenous growth factors promotes wound healing in vivo [2] [3] [4] .
(equimolar ratio) significantly stimulated granulation tissue formation (p < 0.01) and capillary numbers (p < 0.05). Doses of rhIGFBP-1 greater than 16.5 ILg were required for significant acceleration of the healing stimulated by 50 ILg of rhIGF-I. In normal rabbits, co-administration of10 ILg rhIGF-I and 33 ILg rhIGFBP-1 (equimolar ratio) significantly stimulated all t hree wound-healing parameters (p < 0.01), with such stimulation being much greater than that induced by rhIGF-I alone. Interestingly, rhIGFBP-1 alone showed a mild stimulatory activity on wound healing in both models despite its lack of mitogenic activity in vitro. These results demonstrate that rhIG-FBP-1 enhances the stimulatory activity of rhIGF-I on wound healing and suggest the clinical utility o f t he co-administration of rhIGF-I and rhIGFBP-1 for wound repair. K ey words: IGFBP-1/diabetic mouse/rabbit ear. J Invest D ermatol 104:199-203, 1995 [8] [9] [10] , sometimes in a paracrine manner [11] , and promotes granulation tissue formation in animal wound-healing models either alone [12] or in combination with other growth factors [2] . IGF-I is produced mainly in the liver and circulates in the bloodstream to target organs. IGF-I also is secreted from migrated platelets, macrophages, and fibroblasts in wounds [13] and IGF-I mRNA is detectable at the wound site [14, 15] .
A characteristic ofIGF-I and IGF-II that distinguishes them from other growth factors is the existence of specific IGF-binding proteins, designated as insulin-like growth factor-binding proteins (IGFBPs) [5, 6, 13, 16] . So far, six related peptides (IGFBP-1-6) have been cloned and characterized. IGFBPs form complexes with IGF-I and IGF-II in plasma and in tissues and are believed to play important roles as regulators of IGF bioavailability and bioactivity. IGFBPs also have been shown to protect IGF-I from proteolytic degradation. IGFBP-3 is the most abundant IGFBP in plasma, where it circulates as part of a large, 150-kDa complex that is believed to function as a carrier and reservoir of IGF-I in plasma [5, 16] . IGFBP-1 [17] , a small, 25-kDa binding protein produced mainly in the liver and by fibroblasts, can distribute between the circulation and tissues and may playa role as a regulator of IGF-I bioavailability in both compartments [5, 16] .
IGFBP-1 can inhibit the action of IGF-I on cells by forming a complex, which prevents IGF-I from binding to its receptor on the cell membrane [18 -24] . However, depending on the experimental conditions or cell types, IGFBP-1 can potentiate the action ofIGF-I 0022-202X/95/$09 .50 • SSDI0022-202X(94)00322-X • Copyright © 1995 by The Society for Investigative Dermatology, Inc. 199 on cultured cells [25] [26] [27] . The precise mechanism of the interaction of IGF-I and IGFBP-l that results in stimulation or inhibition of IGF-I action is not well understood.
In the present study, the effect of recombinant human IGFBP-l and/ or IGF-I on wound healing was tested using a healingimpaired db/db mouse model [3] , and the stimulatory effect of co-administration of IGF-I and IGFBP-l on wound healing was confirmed by another wound-healing model using normal rabbit ears.
MATERIALS AND METHODS
Reagents Recombinant human IGF-I (rhIGF-I) and recombinant human IGFBP-l (rhIGFBP-l, nonphosphorylated form) were prepared using a bacterial expression vector system [24] . Fractions containing greater than 95% pure recombinant materials were used for the experiments. The vehicle solution consisted of 0.1% bovine serum albumin (BSA. Sigma A-4919, St. Louis, MO) in sterilized phosphate-buffered saline (PBS). A 30-I.Ll BSA-PBS solution containing different concentrations of rhIGF-I and/or rhIGFBP-l was applied to each wound.
Animals and Wounding Wounding design and sample preparation were performed according to our previously reported method [3] . Female mutant diabetic mice, C57BL/ksJ db/db, were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were housed individually and maintained on a standard laboratory diet and received water ad libitum. Mice at 8 weeks of age were anesthetized with sodium pentobarbital solution (25 mg/kg, injected intraperitoneally, Abbott Laboratories, North Chicago, IL) and their dorsal hair was shaved. Two full-thickness round wounds were prepared on the back of each mouse in the anterior-posterior direction using a punch biopsy instrument (6 mm diameter, Maruho Co., Osaka, Japan) . Each mouse received the same test solution on both wounds (30 /Ll each) once daily until the fifth day. The wounds were left open throughout the experiment, and the mice were killed on the eighth day by cervical dislocation. The wounds were excised and fixed in 10% buffered formalin solution.
Female white rabbits (Shiraishi Laboratory Animals, Tokyo, Japan), each weighing 2.5 kg, were anesthetized with sodium pentobarbital solution (40 mg/kg, Abbott Laboratories) and ketarnine hydrochloride solution (15 mg/kg, Sankyo Co., Tokyo, Japan). Four full-thickness round wounds were prepared on the inner side of each ear using a punch-biopsy instrument (6 mm diameter). The perichondrium was kept undamaged. The wounds were covered with a sterilized transparent dressing (Cathereep, Nichiban Co., Tokyo, Japan), and the 30-/Ll test solution applied to each wound using a syringe. The four wounds in each ear received the same test sol ution . The ear was bandaged and kept covered throughout the experiment. The rabbits were killed on the seventh day by intravenous administration of pentobarbital solution. The wounds were excised and fixed in 10% buffered formalin solution.
Histologic Evaluation After overnight fixation, the tissue was trimmed and cut through at the widest margin. The tissue was embedded in paraffin and sectioned in 5-/Lm increments. The sections were made perpendicular to the anterior-posterior axis and perpendicular to the surface of the wound. Three sections were placed on a slide, and stained with hematoA}'lin and eosin. Of the three sections on anyone slide, the section with the widest original wound margin was used for assessment. The parameters measured were degree of re-epithelialization, area of granulation tissue, and number of capillaries. Each of the parameters was graded numerically as described below.
R e-Epithelialization: The degree of re-epithelialization was measured by a computerized morphometric analysis (IBAS-2000, Zeiss, Germany) and was given a value by percentage; 0% was equivalent to no closure and 100% was equivalent to complete wound closure.
Area of Granulation Tissue: The amount of granulation tissue was quantified by measuring the area of granulation tissue (mm 2 ) in the section perpendicular to the surface of the wound. Granulation tissue was traced by a computerized morphometric analysis (IBAS-2000).
Capillary Number: The number of capillary lumens in the granulation tissue was counted in the complete wound cross-section at 100 X magnification.
Statistical Analysis All data were analyzed by one-way analysis of variance using Bonferroni's procedure. The results were expressed as means ± SEM.
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RESULTS
Effect ofrhIGF-I and rhIGFBP-l on wound healing in dbldl mice Initially, the dose response of an equimolar ratio of rhIGF-l and rhIGFBP-l was tested using healing-impaired diabetic mice. A~ the molecular sizes of the recombinant rhIGF-I and rhIGFBP-l are 7.5 kDa and 25 kDa, respectively, the experiments were carried out with a 1 to 4 weight ratio of the two proteins to make them approximately equimolar. A test group in the initial experiment received a 1 to 2 weight ratio of the proteins (50 ILg rhIGF-I plus 100 ILg rhIGFBP-1) because of the difficulties encountered in concentrating the proteins. Figure 1 shows that with application of increasing amounts of the combination ofrhIGF-1 and rhIGFBP-1, wound healing, as measured by three parameters-re-epithelialization, new granulation tissue, and capillary number-became accelerated (n = 7 per group). The combination of rhIGF-I and rhIGFBP-l, in doses greater than 10 ILg and 40 ILg, respectively, appeared to have a stimulatory effect on wound healing, although statistical significance was not achieved. Subsequently, using the larger amounts of rhIGF-I and rhIGFBP-1 (50 ILg and 165 ILg, respectively), the effects of rhIGF-I alone, rhIGFBP-l alone, and the combination of the two proteins were analyzed. Figure 2 shows that the wounds treated with the combination ofrhIGF-I and rhIGFBP-1 had significant stimulatory effects on granulation tissue formation (p < 0.01) and capillary numbers (p < 0.05). No significant stimulatory effects were seen on re-epithelialization. The wounds treated with rhIGF-I alone also showed a stimulatory effect on granulation tissue formation and capillary numbers. Interestingly, wounds treated with rhIGFBP-1 alone also showed a mildly positive effect on wound healing even though IGFBP-1 has been reported as being a non-mitogenic material ( [27] and our unpublished data). Significant difference (p < 0.05) was observed between those groups treated by rhIGFBP-1 alone and those treated by the co-administration ofrhIGF-I and rhIGFBP-1, especially with regard to granulation tissue formation. Typical examples of the histology obtained in the experiment (Fig 2) are illustrated in Fig  3. It is apparent that thick and dense granulation tissue was formed in wounds treated with the combination ofrhIGF-I and rhIGFBP-1. In the next experiment, 50 ILg of rhIGF-I was applied to the wounds with different doses of rhIGFBP-l (1.65 ILg, 16.5 ILg, or 165 ILg) to find the optimal ratio of the two agents. Figure 4 shows that an increase in the amount of rhIGFBP-l enhanced the wound healing stimulated by 50 ILg rhIGF-I, as measured by granulation respectively) showed better healing scores than a single application of the same dose of the two factors (Fig 4) .
Effect of rhIGF-I and rhIGFBP-1 on Wound Healing in Normal Rabbits
As an open wound assay system, db/db mice may not necessarily be an appropriate method by which to evaluate the degree of re-epithelialization due to the large scab formation [3] . Therefore, experiments with a closed wound assay system were performed using normal rabbit ears. Preliminary experiments suggested that 10 JLg of rhIGF-I was enough to show a stimulatory effect on wound healing in normal rabbits (data not shown). An experiment was designed to examine the stimulatory effect of rhIGF-I in the presence or absence of equimolar rhIGFBP-1. Figure 5 shows that the wounds treated with the combination of rhIGF-I (10 JLg) and rhIGFBP-1 (33 JLg) had significant stimulatory effects on re-epithelialization (p < 0.01) as well as on capillary numbers (p < 0.01). The wounds treated with the combination of rhIGF-I and rhIGFBP-1 had greater wound-healing responses, as measured by all three wound-healing parameters, than those wounds treated with rhIGF-I alone. The wounds treated with IGFBP-1 alone also had a mildly positive, but not statistically significant, effect on wound healing as was observed in db/db mice. Typical examples of the histology obtained in the experiment ( Fig  5) are illustrated in Fig 6. It is apparent that thick granulation tissue and accelerated wound closure were achieved in wounds treated with the combination of rhIGF-I and rhIGFBP-1.
DISCUSSION
The results clearly demonstrated that the co-administration of rhIGF-I and rhIGFBP-1 stimulates wound healing in both normal and healing-impaired animals. The healing stimulation induced by the co-administration of rhIGF-I and rhIGFBP-1 was greater than that induced respectively by rhIGF-I, rhIGFBP-1, or vehicle alone. Although variations in the data among the experiments were observed due to the in vivo experiments, and also because of a limited number of animals and limited amount of concentrated reagents, especially in the initial experiment, some interesting aspects were raised in terms of the interaction between IGF-I and IGFBP-l in vivo. The minimum dose ofrhlGF-1 required to induce wound healing in db/db mice and nonnal rabbits appeared to be 10 /-Lg (Figs 1 and 5); however, we used 50 /-Lg of rhIGF-I in most experiments with db/db mice to ensure the positive effect of rhlGF-1. In the coadministration group, Fig 4, we tested rhIGF-I:rhIGFBP-l in molar ratios of 100:1, 10:1, and 1:1, using a constant amount of rhIGF-I (50 /-Lg). Doses of rhIGFBP-l greater than 16.5 /-Lg (10:1 IGF-I: IGFBP-l molar ratio) were required for significant acceleration of the healing stimulated by 50 /-Lg of rhlGF-1. From the results we can infer that the application of equimolar rhIGF-I and rhIGFBP-l has the greatest stimulatory activity at this rhIGF-I dose. We did not test IGF-I:IGFBP-l molar ratios less than 1:1; i.e., IGFBP-l molar excess, because of difficulties in preparing highly concentrated rhIGFBP-l solutions.
When comparing the results of Figs 2 and 5, the stimulatory activity of rhIGFBP-l on rhIGF-I-stimulated wound healing was more pronounced in normal rabbits than in db/db mice. This may be because we used a higher dose of rhIGF-I (50 /-Lg) with db/db mice than with nonnal rabbit (10 /-Lg). The higher rhIGF-I dose used in the mouse studies may have come close to maximizing the potential rhIGF-I response and providing a smaller window in which to detect stimulation by rhIGFBP-1. This situation may be analogous to what is observed in vitro where, at high concentrations, the stimulatory effect ofrhlGF-1 on cell proliferation plateaus. IGFBP-l potentiates the proliferative response of cultured keratinocytes to IGF-I [27] ; however, similar to what was observed in the woundhealing experiments, the potentiating effect of rhIGFBP-l on rhIGF-I-stimulated keratinocyte proliferation in vitro is mild at high concentrations ofrhlGF-1 (our unpublished data). An alternative possibility for the more pronounced stimulatory effect of rhIGFBP-l on rhIGF-I-stimulated wound healing in normal rabbits may be differences in circulating IGFBP-l levels in nonnal rabbits and db/db mice. Plasma levels of IGFBP-l are negatively regulated by insulin levels and are elevated in diabetes mellitus patients [28, 29] . It is possible that the endogenous IGFBP-l level in db/db mice is high enough to potentiate a wound-healing response to an exogenous application of rhlGF-1.
Interestingly, rhIGFBP-l alone had a mildly stimulatory effect on wound healing even though IGFBP-l has been reported to be non-mitogenic ( [27] and our unpublished data). This may have occurred as a result of the exogenous application of rhIGFBP-l stimulating endogenous IGF-I present at the wound site. Some IGF-I would be expected to be present at the wound site as a result of being brought in by the circulation and as a result of secretion and/ or synthesis by platelets, macrophages or fibroblasts at the wound site. Another possibility is that the direct healing-stimula-THE JOURNAL OF INVESTIGATIVE DERMATOLOGY tory aCtIvIty of rhIGFBP-l results from its IGF-I-independent migration stimulatory actions [30] .
The stimulatory effect of IGFBP-l for the mitogenic effects 01 IGF-I on fibroblasts [25] [26] [27] and keratinocytes [27] has been shown in vitro. Hamon et al [31] recently demonstrated that the systemic administration of IGF-I:IGFBP-3 complex was effective in reversing corticosteroid-induced suppression of DNA and protein synthesis in rats. The precise mechanism by which IGFBP-l , and other IGFBPs, stimulate the mitogenic effects of IGF-I is not yet understood. Cumulative data in the literature suggest the following possible explanations. 1) IGFBP-l could extend the half-life of IGF-I at the wound site by fonning a complex [5, 6, 13, 16] . The somewhat greater stimulatory effect by the combination of rhIGF-I and rhIGFBP-l in the multiple application group than in the single application group (Fig 4) suggests a limited life span of rhIGF-I and rhIGFBP-l at the wound site. 2) IGFBP-l, a smaller-molecularweight binding protein, can cross the capillary boundaries [32] and may act to transport IGF-I from the vasculature to IGF target cells. .,1.::.,. 1,,4" '" 3) IGFBP-1 binds the (XS{31 integrin on the cell membrane by means of its Arg-Gly-Asp sequence [30] . IGF-I may associate with cellbound IGFBP-1 and be more accessible to IGF receptors. This also may be a mechanism whereby IGFBP-1 could prolong the half-life of IGF-I at the wound site. 4) The IGF-I-independent migrationstimulatory activity (and other potential, uncharacterized activities) of IGFBP-1 [30] may allow cells to respond more vigorously to IGF-I stimulation. 5) IGFBP-1 may protect IGF-I from proteolytic degradation at the wound site. Further studies with in vitro and in vivo models are necessary to obtain a detailed understanding of IGFBP-1's stimulation mechanism. IGF-I has been proposed as a healing-potentiating agent [2, 12] . The present study demonstrates that the co-administration of rhIGF-I and rhIGFBP-1 induces greater stimulatory activity than rhIGF-I alone. Although we did not perform comparative studies with other growth factors, the potent activity of the combination of rhIGF-I and rhIGFBP-1 in several wound models suggest their potential clinical utility as healing-stimulatory agents.
